Coverage
Filings
Orion's collaboration partner Bayer announced U.S. FDA approval for darolutamide, an androgen receptor inhibitor (ARi), for metastatic hormone-sensitive prostate cancer (mHSPC).
| 27 Jan 2015 |
| Publishing of Orion Corporation's Financial Statement Release for 2014 on 4 February 2015 | 23 Jan 2015 |
| 200,000 Orion Corporation A shares converted into B shares | 16 Dec 2014 |
| 6,335 Orion A shares converted into B shares | 21 Nov 2014 |
| Composition of the Nomination Committee of Orion Corporation | 22 Oct 2014 |